Author:
Bellagamba Rita,Giancola Maria Letizia,Tommasi Chiara,Piselli Pierluca,Tempestilli Massimo,Angeletti Claudio,Zaccarelli Mauro,Ammassari Adriana,Pinnetti Carmela,Gallo Anna Loredana,Antinori Andrea,Narciso Pasquale,Nicastri Emanuele
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference20 articles.
1. Tenofovir disoproxil fumarate for the treatment of HIV infection;Pham;Expert Opin Drug Metab Toxicol,2006
2. Pharmacokinetic and pharmacodynamic characteristics of Emtricitabine support its once daily dosing for the treatment of HIV infection;Wang;AIDS Res Hum Retroviruses,2004
3. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks;Sax;Lancet,2012
4. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients;Dejesus;JAIDS,2009
5. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet;Frampton;Drugs,2006
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression;Open Forum Infectious Diseases;2023-05
2. Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study;International Journal of Infectious Diseases;2022-04
3. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial;The Lancet HIV;2022-02
4. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression;J MICROBIOL IMMUNOL;2021
5. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression;Journal of Microbiology, Immunology and Infection;2021-10